ASH 2020 Investor Conference Call: Pioneering the Development of Engineered IgM Antibodies

IGM Investor Conference Call Presentation at the 62nd ASH Annual Meeting and Exposition December 5, 2020

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020 Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies Number: ...

The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020 Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents Abstract Number: 2093, December 6, ...

Abstract 2093: The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

The 62nd ASH Annual Meeting and Exposition – December 5-8, 2020

Abstract 1142: Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

The 62nd ASH Annual Meeting and Exposition – December 5-8, 2020

Poster: Targeting IL-15 delivery to PD-L1 Expressing Tumors using an Anti-PDL1 x IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity

Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020

Abstract: Targeting IL-15 delivery to PD-L1 Expressing Tumors with an Anti-PD-L1-IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity

Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020

Immunologic Mechanisms and Engineering Objectives: Case Study of Anti-PD-L1 x IL-15

PEGS Europe Virtual – November 11, 2020 Program: Advancing Bispecifics and Combination Therapy to the Clinic

Clinical Challenges and Engineering Solutions in Cancer Immunotherapy: What Do We Need Now?

PEGS Europe Virtual – November 12, 2020 Programs: Keynote Presentation in Novel Targets and Emerging Therapeutic Areas & in Engineering Bispecific Antibodies

Agonist IgM: Anti-Death Receptor 5 IgM Induces Tumor Cell Apoptosis in vitro and in vivo with a Favorable Safety Profile

PEGS Europe Virtual – November 12, 2020 Program: Novel Targets and Emerging Therapeutic Areas

IgM Antibodies with Very Potent Agonism for DR5-Induced Apoptosis and as Anti-Tumor Agents

PEGS Boston Virtual – August 31-September 4, 2020

A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release

AACR Virtual Annual Meeting II: June 22-24, 2020

Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile

AACR Virtual Meeting II – June 22 – 24, 2020 Poster Session: Antibody Technologies – Experimental and Molecular Therapeutics Abstract: 518 / 2, E-Poster: June ...

Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323)

ASCO20 Virtual Scientific Program – May 29-31, 2020 Session: Developmental Therapeutics–Immunotherapy Abstract # e15007

IGM-8444 as a potent agonistic Death Receptor 5 (DR5) IgM antibody: Induction of tumor cytotoxicity, combination with chemotherapy and in vitro safety profile.

ASCO20 Virtual Scientific Program – May 29-31, 2020 Poster Session: Developmental Therapeutics–Molecularly Targeted Agents and Tumor Biology Abstract # 3595

A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release

AACR Virtual Meeting II – June 22 – 24, 2020 Session: Therapeutics Antibodies 4 – Immunology Abstract: 5664 / 25 E-Poster: June 22, 2020, 9:00 ...